BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AFSSI Sciences de la Vie - ECPv5.14.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AFSSI Sciences de la Vie
X-ORIGINAL-URL:https://www.afssi.fr
X-WR-CALDESC:Events for AFSSI Sciences de la Vie
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20231026T170000
DTEND;TZID=Europe/Paris:20231026T170000
DTSTAMP:20260525T144954
CREATED:20231005T075333Z
LAST-MODIFIED:20231009T074630Z
UID:232067-1698339600-1698339600@www.afssi.fr
SUMMARY:Webinar ProteoGenix - The use of phage display for human antibody development
DESCRIPTION:Overcome the Multiple Challenge of Neutralizing Antibodies in Cancer Therapy Using Innovative Phage Display Technologies\nWhile Phage Display panning on naïve libraries combined with costly affinity maturation strategies have allowed the successful development of neutralizing antibodies\, it also leads to failures and aborted projects. One reason for this is the immune tolerance of a naïve library that is sometimes ineffective at identifying binders against important and/or highly expressed human targets. An efficient way to access high-affinity\, fully human antibodies against such targets is thus essential for human cancer therapy. \n\n\n\n  \nIn this webinar\, ProteoGenix will discuss innovative technologies to develop such antibodies using human phage display. These strategies include: \n\nA cross-panning protocol for a successful identification of neutralizing binders.\nPhage display libraries to allow an efficient identification of neutralizing binders through competitive ELISA.\nA new human cancer library constructed from the PBMCs of cancer patients as an efficient solution to counter immune tolerance.\n\n\n\n\n\nKey Topics Include:\n\n\nEfficient identification of neutralizing antibodies\nStrategic development of human phage libraries to break immune tolerance\nStrategies to augment phage display-based discovery\n\n\n\n\nSpeaker\n\nConor McCartin\, PhD\, Account Manager Monoclonal Antibody Development\, ProteoGenix\n\nAbout ProteoGenix\nFounded in 2003\, ProteoGenix has evolved from its roots in developing diagnostic assays and biotherapeutics to become a leading contract research organization and a trusted partner in the biopharma industry. With a focus on high-quality antibodies and proteins\, the company plays a pivotal role in advancing biomolecules from early discovery to clinical applications. Offering comprehensive services in six key areas—antibody engineering\, bioprocess development\, monoclonal and polyclonal antibody development\, recombinant protein and antibody production\, gene synthesis\, and peptide synthesis—ProteoGenix is a one-stop solution for researchers and developers. With over 15 years of experience\, innovative R&D contributions like the XtenCHO™ cell line\, and an extensive catalog of over 200\,000 products\, ProteoGenix stands as a cornerstone in the life sciences community\, dedicated to improving the success rate of clinical applications in biopharma. \n  \nRegistration
URL:https://www.afssi.fr/event/webinar-use-phage-display-human-antibody-development/
LOCATION:en ligne\, France
CATEGORIES:Evénement filière,Evénement partenaire
ATTACH;FMTTYPE=image/png:https://www.afssi.fr/wp-content/uploads/2023/10/Webinaire-ProteoGenix.png
END:VEVENT
END:VCALENDAR